Severe Ulceronecrotic Evolution during Mogamulizumab Treatment in a Patient with Primary Cutaneous Peripheral T-cell Lymphoma
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0279Keywords:
Cutaneous T-Cell Lymphoma, mogamulizumab, Drug-Related side effects and adverse reactions, pharmacovigilance, primary cutaneous peripheral T-cell lymphomaDownloads
References
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018; 19: 1192–1204. DOI: https://doi.org/10.1016/S1470-2045(18)30379-6
Poteligeo. European Medicines Agency (EMA). 2018. [cited 2025 November 21]. Available from: https://www.ema. europa.eu/en/medicines/human/EPAR/poteligeo
Kempf W, Mitteldorf C, Cerroni L, Willemze R, Berti E, Guenova E, et al. Classifications of cutaneous lymphomas and lymphoproliferative disorders: An update from the EORTC cutaneous lymphoma histopathology group. J Eur Acad Dermatol Venereol 2024; 38: 1491–1503. DOI: https://doi.org/10.1111/jdv.19987
G, Roccuzzo G, Pileri A, Agostinelli C, Maronese CA, Aquino C, et al. Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: a systematic review. J Eur Acad Dermatol Venereol 2024; 38: 1738–1748. DOI: https://doi.org/10.1111/jdv.19801
Hansen I, Abeck F, Menz A, Schneider SW, Booken N. Mogamulizumab-associated rash - case series and review of the literature. J Dtsch Dermatol Ges 2024; 22: 1079–1086. DOI: https://doi.org/10.1111/ddg.15432
Barré M, Valois A, Okhremchuk I, Sair M, Masbou J, Abed S, et al. Ecthyma gangrenosum complicating mogamulizumab treatment of Sézary syndrome. Ann Dermatol Venereol 2021; 148: 63–65. DOI: https://doi.org/10.1016/j.annder.2020.09.576
Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 1985; 40: 111–118.
Suzuki Y, Saito M, Ishii T, Urakawa I, Matsumoto A, Masaki A, et al. Mogamulizumab treatment elicits autoantibodies attacking the skin in patients with adult T-cell leukemialymphoma. Clin Cancer Res 2019; 25: 4388–4399. DOI: https://doi.org/10.1158/1078-0432.CCR-18-2575
Published
How to Cite
Issue
Section
Categories
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
